Company Profile

Avidity Biosciences Inc (AKA: Avidity Nanomedicines LLC)
Profile last edited on: 6/9/2024      CAGE: 6T4L7      UEI: LX2MEK2LZWB3

Business Identifier: New class of oligonucleotide-based therapies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

10578 Science Center Drive Suite 125
San Diego, CA 92121
   (858) 401-7900
Location: Single
Congr. District: 50
County: San Diego

Public Profile

Previously dba Avidity NanoMedicines LLC, Avidity Biosciences is a biopharmaceutical company focused on advancing a new class of precision medicines – Antibody-siRNA Conjugates (ASC™). The latter are designed to combine the strengths of monoclonal antibodies and siRNA-based therapeutics - drawing down on the best features of both antibody-drug conjugates and nucleic acid-based medicines and utilizing nano-scale self-assembly to create a transformative approach to the treatment of cancer and other serious diseases. Although nucleic acid-based therapeutics have demonstrated success in targeting the liver, systemic bioavailability remains a challenge. The technology under development by Avidity combines the potency and specificity of biologics with nanoparticle technology and precise molecular targeting to create a platform that can be tailored to specific tumors.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $200,000
Project Title: Rnai Cancer Therapeutics Using Nanotechnology. Phase I. Hhsn26120

Key People / Management

  Oren Gilad -- Co-founder, President & CEO

  Troy Wilson -- Founder, President and Chief Executive Officer

  Mark E Davis -- Scientific Founder

  Andrew J Geall -- Vice President, Formulations & Chemistry

  P Kent Hawryluk -- Co-Founder and Chief Business Officer

  Vanessa L Jacoby -- Vice President, Finance

  Arthur A Levin -- Executive Vice President of Research and Development

  Frank Mccormick -- Scientific Founder

  Kevin D Smith -- Co-Founder

  John Wallen -- Vice President, Intellectual Property